Patents by Inventor John Aitchison

John Aitchison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230331824
    Abstract: Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 19, 2023
    Applicants: The Rockefeller University, Seattle Children's Hospital d/b/a Seattle Children's Research Institute, New York University
    Inventors: Brian T. Chait, Michael P. Rout, John Aitchison, Fred David Mast, Jean Paul Olivier, David Fenyo
  • Publication number: 20150275262
    Abstract: A method of high-density, multiparameter growth analysis founded upon modeling microcolony expansion on solid media is described. The method extracts the key growth parameters (lag time, doubling time, carrying capacity and viability) that together define microcolony growth from seeded cells. The invention relates to a method to determine growth parameters of cells that is scalable, time-resolved and quantitative.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Inventors: Alex Ratushny, David Dilworth, John Aitchison
  • Patent number: 7148215
    Abstract: The present invention concerns compounds of general formula (I): in which the substituents are as described herein.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: December 12, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Andrew James Ratcliffe, Roger John Aitchison Walsh, Tahir Nadeem Majid, Sukanthini Thurairatnam, Shelley Amendola, David John Aldous, John Edward Souness, Conception Nemecek, Sylvie Wentzler, Corinne Venot
  • Patent number: 6211234
    Abstract: Compounds of formula (I) are described wherein R1 is hydrogen, -(lower alkyl)q(CO2R6 or OH), —CN, —C(R7)═NOR8, NO2, —O(lower alkyl)R9, —C≡C—R10, —CR11═C(R12)(R13), —C(═O)CH2C(═O)CO2H, —CO(R14), alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, thiocarbamoyl, substituted carbamoyl, substituted thiocarbamoyl, sulphamoyl or an optionally substituted nitrogen-containing ring, m, n, o and p are independently zero or 1 and R2, R3, R4 and R5 are various groups; and physiologically acceptable salts, N-oxides and prodrugs thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: April 3, 2001
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Peter Charles Astles, Mark Francis Harper, Neil Victor Harris, Iain McFarlane McLay, Roger John Aitchison Walsh, Richard Alan Lewis, Christopher Smith, Barry Porter, Clive McCarthy